peroxisome proliferator activated receptors

Summary

Summary: TRANSCRIPTION FACTORS that are activated by ligands and heterodimerize with RETINOID X RECEPTORS and bind to peroxisome proliferator response elements in the promoter regions of target genes.

Top Publications

  1. ncbi Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARdelta agonist, on development of steatohepatitis in mice fed a methionine- and choline-deficient diet
    Tatsuya Nagasawa
    Toxicology Research Laboratory, R and D, Kissei Pharmaceutical Co, Ltd, 2320 1 Maki, Hotaka, Azumino City, Nagano Pref, 399 8305, Japan
    Eur J Pharmacol 536:182-91. 2006
  2. ncbi Molecular mechanisms of cross-talk between thyroid hormone and peroxisome proliferator activated receptors: focus on the heart
    Outi M Hyyti
    Division of Cardiology, Department of Pediatrics, Childrens Hospital and Regional Medical Center, 4800 Sandpoint Way NE, 4G-1, Seattle, WA 98105, USA
    Cardiovasc Drugs Ther 20:463-9. 2006
  3. ncbi Peroxisome proliferator-activated receptor expression and activation in normal human colonic epithelial cells and tubular adenomas
    Mads Wichmann Matthiessen
    Department of Medical Gastroenterology C112, Herlev University Hospital, 2730 Herlev, Denmark
    Scand J Gastroenterol 40:198-205. 2005
  4. ncbi Polyunsaturated fatty acid regulation of genes of lipid metabolism
    Harini Sampath
    Department of Nutritional Sciences, University of Wisconsin Madison, Madison, Wisconsin 53706, USA
    Annu Rev Nutr 25:317-40. 2005
  5. ncbi Peroxisome proliferator-activated receptors as sensors of fatty acids and derivatives
    P A Grimaldi
    Inserm U636, Centre de Biochimie, UFR Sciences, Universite de Nice Sophia Antipolis, Parc Valrose, 06108, Nice, France
    Cell Mol Life Sci 64:2459-64. 2007
  6. ncbi Therapeutic roles of peroxisome proliferator-activated receptor agonists
    Bart Staels
    Department of Atherosclerosis, Unité INSERM 545 Institut Pasteur, 1, rue du Professeur Calmette, 59019 Lille Cedex, France
    Diabetes 54:2460-70. 2005
  7. ncbi The human semaphorin 6B gene is down regulated by PPARs
    Philippe Collet
    EA 3446 Peroxisome Proliferators, Faculty of Sciences, BP 239, University Henri Poincaré Nancy 1, 54506 Vandoeuvre les Nancy, France
    Genomics 83:1141-50. 2004
  8. ncbi Modulation of HepG2 cell net apolipoprotein B secretion by the citrus polymethoxyflavone, tangeretin
    Elzbieta M Kurowska
    KGK Synergize Inc, Research and Development Division, London, Ontario, Canada N6A 5R8
    Lipids 39:143-51. 2004
  9. ncbi Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons
    Alexander Tenenbaum
    Cardiac Rehabilitation Institute, Sheba Medical Center, 52621 Tel Hashomer, Israel
    Cardiovasc Diabetol 4:14. 2005
  10. ncbi Be fit or be sick: peroxisome proliferator-activated receptors are down the road
    Beatrice Desvergne
    Center for Integrative Genomics, University of Lausanne, Biology Building, CH 1015 Lausanne Dorigny, Switzerland
    Mol Endocrinol 18:1321-32. 2004

Research Grants

  1. Limiting Inflammation in the CF Lung
    Pamela Davis; Fiscal Year: 2007
  2. Beta-cell Compensation in Partial Pancreatectomy Mice
    JOHN L LEAHY; Fiscal Year: 2010
  3. Molecular targeting of PPAR-delta in colon cancer
    Imad Shureiqi; Fiscal Year: 2010
  4. 15-LOX-1 effects on colitis and colon cancer
    Imad Shureiqi; Fiscal Year: 2009
  5. 15-LOX-1 effects on colitis and colon cancer
    Imad Shureiqi; Fiscal Year: 2010
  6. MOLECULAR BASIS OF HIV LIPODYSTROPHY: ROLE OF VPR
    Ashok Balasubramanyam; Fiscal Year: 2003
  7. ROLE OF PPAR GAMMA IN LUPUS NEPHRITIS
    Gary Gilkeson; Fiscal Year: 2005
  8. PPAR-gamma Signaling in Normal Pilosebaceous Units and in Scarring Alopecia
    Pratima Karnik; Fiscal Year: 2010
  9. Transcriptional Control of Macrophage in Atherogenesis
    Ajay Chawla; Fiscal Year: 2010
  10. Action of Anabolic Factors on Bone Formation in Mice
    MARJA MARIE HURLEY; Fiscal Year: 2010

Detail Information

Publications215 found, 100 shown here

  1. ncbi Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARdelta agonist, on development of steatohepatitis in mice fed a methionine- and choline-deficient diet
    Tatsuya Nagasawa
    Toxicology Research Laboratory, R and D, Kissei Pharmaceutical Co, Ltd, 2320 1 Maki, Hotaka, Azumino City, Nagano Pref, 399 8305, Japan
    Eur J Pharmacol 536:182-91. 2006
    ....
  2. ncbi Molecular mechanisms of cross-talk between thyroid hormone and peroxisome proliferator activated receptors: focus on the heart
    Outi M Hyyti
    Division of Cardiology, Department of Pediatrics, Childrens Hospital and Regional Medical Center, 4800 Sandpoint Way NE, 4G-1, Seattle, WA 98105, USA
    Cardiovasc Drugs Ther 20:463-9. 2006
    Thyroid hormone receptors (TR) and peroxisome proliferator activated receptors (PPAR) regulate cardiac metabolism...
  3. ncbi Peroxisome proliferator-activated receptor expression and activation in normal human colonic epithelial cells and tubular adenomas
    Mads Wichmann Matthiessen
    Department of Medical Gastroenterology C112, Herlev University Hospital, 2730 Herlev, Denmark
    Scand J Gastroenterol 40:198-205. 2005
    ..Moreover, they raise interest in investigation of PPAR alpha as a therapeutic target to prevent adenoma formation...
  4. ncbi Polyunsaturated fatty acid regulation of genes of lipid metabolism
    Harini Sampath
    Department of Nutritional Sciences, University of Wisconsin Madison, Madison, Wisconsin 53706, USA
    Annu Rev Nutr 25:317-40. 2005
    ..Working out the mechanisms by which these interactions and consequent effects occur is proving to be complicated but is invaluable to our understanding of the role that dietary fat can play in disease management and prevention...
  5. ncbi Peroxisome proliferator-activated receptors as sensors of fatty acids and derivatives
    P A Grimaldi
    Inserm U636, Centre de Biochimie, UFR Sciences, Universite de Nice Sophia Antipolis, Parc Valrose, 06108, Nice, France
    Cell Mol Life Sci 64:2459-64. 2007
    ....
  6. ncbi Therapeutic roles of peroxisome proliferator-activated receptor agonists
    Bart Staels
    Department of Atherosclerosis, Unité INSERM 545 Institut Pasteur, 1, rue du Professeur Calmette, 59019 Lille Cedex, France
    Diabetes 54:2460-70. 2005
    ..The functions of a third PPAR isoform, PPARdelta, and its potential as a therapeutic target are currently under investigation...
  7. ncbi The human semaphorin 6B gene is down regulated by PPARs
    Philippe Collet
    EA 3446 Peroxisome Proliferators, Faculty of Sciences, BP 239, University Henri Poincaré Nancy 1, 54506 Vandoeuvre les Nancy, France
    Genomics 83:1141-50. 2004
    ..In addition, cross talk between the peroxisome proliferator and retinoic acid pathways is suggested...
  8. ncbi Modulation of HepG2 cell net apolipoprotein B secretion by the citrus polymethoxyflavone, tangeretin
    Elzbieta M Kurowska
    KGK Synergize Inc, Research and Development Division, London, Ontario, Canada N6A 5R8
    Lipids 39:143-51. 2004
    ..control). The data suggest that tangeretin modulates apoB-containing lipoprotein metabolism through multiple mechanisms...
  9. ncbi Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons
    Alexander Tenenbaum
    Cardiac Rehabilitation Institute, Sheba Medical Center, 52621 Tel Hashomer, Israel
    Cardiovasc Diabetol 4:14. 2005
    ..More powerful new compounds with pan-PPAR activity and proven long-term safety should be highly effective in a clinical setting of patients with coexisting relevant lipid and glucose metabolism disorders...
  10. ncbi Be fit or be sick: peroxisome proliferator-activated receptors are down the road
    Beatrice Desvergne
    Center for Integrative Genomics, University of Lausanne, Biology Building, CH 1015 Lausanne Dorigny, Switzerland
    Mol Endocrinol 18:1321-32. 2004
    ..This review presents a summary of the recent findings on their dual involvement in health and disease...
  11. ncbi Identification and organ expression of peroxisome proliferator activated receptors in brown trout (Salmo trutta f. fario)
    Carla Batista-Pinto
    Laboratory of Cell Biology, ICBAS Institute of Biomedical Sciences Abel Salazar, University of Porto, Portugal
    Biochim Biophys Acta 1731:88-94. 2005
    Although widely studied in mammals, little information about fish peroxisome proliferator activated receptors (PPARs) is yet available...
  12. ncbi International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors
    Liliane Michalik
    Center for Integrative Genomics, National Research Centre Frontiers in Genetics, University of Lausanne, Lausanne, Switzerland
    Pharmacol Rev 58:726-41. 2006
    ..Thus, selective action of PPARs in vivo results from the interplay at a given time point between expression levels of each of the three PPAR and RXR isotypes, affinity for a specific promoter PPRE, and ligand and cofactor availabilities...
  13. ncbi Safety issues and prospects for future generations of PPAR modulators
    Anne Rubenstrunk
    GENFIT, F 59006 Loos, France
    Biochim Biophys Acta 1771:1065-81. 2007
    ..The selective modulation of PPAR activities is a promising approach to develop new drugs with preserved efficacy but diminished adverse effects...
  14. ncbi PPAR- and LXR-dependent pathways controlling lipid metabolism and the development of atherosclerosis
    Andrew C Li
    Department of Cellular and Molecular Medicine, University of California, San Diego, La Jolla, CA 92093, USA
    J Lipid Res 45:2161-73. 2004
    ..Here, we review recent studies that provide new insights into the mechanisms by which these subclasses of nuclear receptors act to systemically influence lipid and glucose metabolism and regulate gene expression within the artery wall...
  15. ncbi A PPAR response element regulates transcription of the gene for human adipose differentiation-related protein
    Paul Targett-Adams
    MRC Virology Unit, Institute of Virology, University of Glasgow, Church Street, Glasgow G11 5JR, UK
    Biochim Biophys Acta 1728:95-104. 2005
    ..These findings offer insight into the mechanisms which serve to regulate ADRP transcription and intracellular lipid storage...
  16. ncbi Kinase signaling cascades that modulate peroxisome proliferator-activated receptors
    Laurent Gelman
    Center for Integrative Genomics, NCCR Frontiers in Genetics, University of Lausanne, Switzerland
    Curr Opin Cell Biol 17:216-22. 2005
    ..The study of this dual regulation mode, which allows PPARs to integrate signals conveyed by lipophilic ligands with those coming from the plasma membrane, may ultimately offer new therapeutic strategies...
  17. ncbi Evaluation of polycyclic aromatic hydrocarbons in the activation of early growth response-1 and peroxisome proliferator activated receptors
    Jeong-Ho Kim
    Department of Pathobiology, University of Tennessee, Knoxville, Tennessee 37996, USA
    Toxicol Sci 85:585-93. 2005
    ..In conclusion, PAHs activate PPAR alpha and PPAR beta/delta, and up-regulate EGR-1 expression in vitro as well as in vivo. These data may provide a diversity of PAH activity in several biological pathways...
  18. ncbi Evolution of peroxisome proliferator-activated receptor agonists
    Feng Chang
    Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI 48201, USA
    Ann Pharmacother 41:973-83. 2007
    ..To discuss the evolution of peroxisome proliferator-activated receptor (PPAR) agonists from single site to multiple subtype or partial agonists for the treatment of type 2 diabetes, dyslipidemia, obesity, and the metabolic syndrome...
  19. ncbi Multiple expression control mechanisms of peroxisome proliferator-activated receptors and their target genes
    Nguan Soon Tan
    Center for Integrative Genomics, NCCR Frontiers in Genetics, University of Lausanne, Biology Building, CH-1015 Lausanne, Switzerland
    J Steroid Biochem Mol Biol 93:99-105. 2005
    ..It is also becoming apparent that understanding the regulation of PPAR expression and activity, can itself have a significant influence on how the expression of subgroups of target genes is studied and integrated in current knowledge...
  20. ncbi An overview on biological mechanisms of PPARs
    Bhavani Prasad Kota
    Faculty of Pharmacy, The University of Sydney, Sydney, NSW 2006, Australia
    Pharmacol Res 51:85-94. 2005
    b>Peroxisome proliferator activated receptors (PPARs) are transcriptional factors belonging to the ligand-activated nuclear receptor superfamily. They are ubiquitously expressed throughout the body...
  21. ncbi PPARs: therapeutic targets for metabolic disease
    Joel P Berger
    Department of Metabolic Disorders, Merck Research Laboratories, Rahway, NJ 07065, USA
    Trends Pharmacol Sci 26:244-51. 2005
    ..Novel PPAR ligands are now being developed that possess broader efficacies and improved tolerability compared with currently available therapeutic agents...
  22. ncbi Suppression of colitis-related mouse colon carcinogenesis by a COX-2 inhibitor and PPAR ligands
    Hiroyuki Kohno
    Department of Oncologic Pathology, Kanazawa Medical University, Uchinada, Ishikawa 920 0293, Japan
    BMC Cancer 5:46. 2005
    ....
  23. ncbi PPARs as drug targets to modulate inflammatory responses?
    Raphael Genolet
    Center for Integrative Genomics, NCCR Frontiers in Genomics, University of Lausanne, CH 1015 Lausanne, Switzerland
    Curr Drug Targets Inflamm Allergy 3:361-75. 2004
    ..We also discuss the potential utilisation of PPAR specific ligands in the treatment of inflammatory diseases, such as inflammatory bowel diseases, atherosclerosis, Parkinson's and Alzheimer's diseases...
  24. ncbi Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors
    S E O'Sullivan
    School of Biomedical Sciences, University of Notttingham, Queen s Medical Center, Nottingham, UK
    Br J Pharmacol 152:576-82. 2007
    ....
  25. ncbi Differential responses of PPARalpha, PPARdelta, and PPARgamma reporter cell lines to selective PPAR synthetic ligands
    Mathieu Seimandi
    , , 60 rue de Navacelles, 34090 Montpellier, France
    Anal Biochem 344:8-15. 2005
    ..We conclude that our stable models allow specific and sensitive measurement of PPAR ligand activities and are a high-throughput, cell-based screening tool for identifying and characterizing PPAR ligands...
  26. ncbi From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions
    Jerome N Feige
    Center for Integrative Genomics, NCCR Frontiers in Genetics, Le Génopode, University of Lausanne, CH 1015 Lausanne, Switzerland
    Prog Lipid Res 45:120-59. 2006
    ..Finally, we discuss how the integration of various intra-cellular signaling pathways allows PPARs to participate to whole-body homeostasis by mediating regulatory crosstalks between organs...
  27. ncbi Fluorescence imaging reveals the nuclear behavior of peroxisome proliferator-activated receptor/retinoid X receptor heterodimers in the absence and presence of ligand
    Jerome N Feige
    Center for Integrative Genomics, NCCR Frontiers in Genetics, University of Lausanne, CH 1015 Lausanne, Switzerland
    J Biol Chem 280:17880-90. 2005
    ....
  28. ncbi Attenuation of progression of insulin resistance in patients with coronary artery disease by bezafibrate
    Alexander Tenenbaum
    Cardiac Rehabilitation Institute, Tel-Hashomer, Israel
    Arch Intern Med 166:737-41. 2006
    ..001). CONCLUSIONS: In patients with coronary artery disease enrolled in our study, as represented by the placebo group, HOMA-IR increased over time. During the 2 years of the follow-up, bezafibrate significantly attenuated this process...
  29. ncbi Interleukin-2 suppression by 2-arachidonyl glycerol is mediated through peroxisome proliferator-activated receptor gamma independently of cannabinoid receptors 1 and 2
    Cheryl E Rockwell
    Department of Pharmacology and Toxicology, Michigan State University, 315 National Food Safety and Toxicology Building, East Lansing, MI 48824-1317, USA
    Mol Pharmacol 70:101-11. 2006
    ..Together, the aforementioned studies identify PPARgamma as a novel intracellular target of 2-AG, which mediates the suppression of IL-2 by 2-AG in a manner that is independent of CB1 and/or CB2...
  30. ncbi Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets
    Jonathan D Brown
    Cardiovascular Division, Brigham and Women s Hospital, Boston, Mass, USA
    Circulation 115:518-33. 2007
    ..Such analysis of the existing PPAR data, the appropriate use of currently approved PPAR agonists, and continued progress in PPAR therapeutics will be predicated on a better understanding of PPAR biology...
  31. ncbi Peroxisome proliferator-activated receptor structures: ligand specificity, molecular switch and interactions with regulators
    Vincent Zoete
    Swiss Institute of Bioinformatics SIB, Quartier Sorge, Batiment Genopode, CH 1015 Lausanne, Switzerland
    Biochim Biophys Acta 1771:915-25. 2007
    ..Finally, the interactions of PPARs LBD with co-activators or co-repressors, as well as with the retinoid X receptor (RXR) are described and considered in relation to PPARs activation...
  32. ncbi Liver X receptor mediates hepatitis B virus X protein-induced lipogenesis in hepatitis B virus-associated hepatocellular carcinoma
    Tae Young Na
    College of Pharmacy, Seoul National University, Seoul, Korea
    Hepatology 49:1122-31. 2009
    ..CONCLUSION: Our results suggest a novel association between HBx and LXR that may represent an important mechanism explaining HBx-induced hepatic lipogenesis during HBV-associated hepatic carcinogenesis...
  33. ncbi Peroxisome proliferator-activated receptor agonists modulate heart function in transgenic mice with lipotoxic cardiomyopathy
    Reeba K Vikramadithyan
    Department of Medicine, Columbia University, New York, NY 10032, USA
    J Pharmacol Exp Ther 313:586-93. 2005
    ..These changes were paralleled by alterations in heart lipid uptake. Overall, PPAR activators exhibit differential effects in this model of lipotoxic dilated cardiomyopathy...
  34. ncbi Pan-PPAR agonist beneficial effects in overweight mice fed a high-fat high-sucrose diet
    Caroline Fernandes-Santos
    Biomedical Center, Institute of Biology, State University of Rio de Janeiro, Brazil
    Nutrition 25:818-27. 2009
    ....
  35. ncbi The insulin-like growth factor-binding protein 1 gene is a primary target of peroxisome proliferator-activated receptors
    Tatjana Degenhardt
    Department of Biochemistry and A I Virtanen Institute, University of Kuopio, FIN 70211 Kuopio, Finland
    J Biol Chem 281:39607-19. 2006
    ..We also show that these additional PPAR binding genes contain a number of candidate PPREs and that their mRNA levels respond quickly to the presence of PPAR ligands, indicating that they are also primary PPAR target genes...
  36. ncbi PPAR agonists modulate human osteoclast formation and activity in vitro
    B Y Chan
    Department of Clinical Biochemistry, Royal Liverpool University Hospital, The University of Liverpool, Liverpool, L69 3GA, UK
    Bone 40:149-59. 2007
    ..In conclusion, this study highlights the potential of PPARs as therapeutic targets in diseases with accelerated osteoclast formation and resorption...
  37. ncbi Genome-wide identification of peroxisome proliferator response elements using integrated computational genomics
    Danielle G Lemay
    United States Department of Agriculture, Agricultural Research Service, Western Human Nutrition Research Center, and Department of Nutrition, University of California-Davis, 95616, USA
    J Lipid Res 47:1583-7. 2006
    ..g., chromatin remodeling, DNA damage response, Wnt, and mitogen-activated protein kinase signaling). This first genome-wide library of high-confidence predicted PPAR target genes will be a valuable resource to PPAR biologists...
  38. ncbi The emerging role of lipoproteins in atherogenesis: beyond LDL cholesterol
    Stephen Nicholls
    Heart Research Institute, Sydney, Australia
    Semin Vasc Med 4:187-95. 2004
    ..As such, these factors have become important targets in the development of effective strategies to prevent atherosclerotic cardiovascular disease...
  39. ncbi Synthesis and evaluation of aminomethyl dihydrocinnamates as a new class of PPAR ligands
    Alan M Warshawsky
    Eli Lilly and Co, Indianapolis, IN 46285, USA
    Bioorg Med Chem Lett 16:6328-33. 2006
    ..Several compounds in this series have demonstrated potent plasma glucose and triglyceride lowering capability in rodent models of type 2 diabetes...
  40. ncbi Nutrients, nuclear receptors, inflammation, immunity lipids, PPAR, and allergic asthma
    Avery August
    Center for Molecular Immunology and Infectious Disease, The Pennsylvania State University, University Park, 16802, USA
    J Nutr 136:695-9. 2006
    ..In vitro, T cells from ciglitazone-treated mice secreted significantly less IL-4 and IFN-gamma in response to restimulation. These data suggest that PPARgamma agonists may be useful for the treatment of allergic asthma...
  41. ncbi Effects of peroxisome proliferator-activated receptor ligands in modulating tissue factor and tissue factor pathway inhibitor in acutely symptomatic carotid atheromas
    Jonathan Golledge
    Vascular Biology Unit, School of Medicine, James Cook University, Townsville, Queensland, Australia
    Stroke 38:1501-8. 2007
    ..We investigated the effect of peroxisome proliferator-activated receptor (PPAR) -alpha and -gamma ligands in acutely modifying tissue factor (TF) and tissue factor pathway inhibitor (TFPI) in unstable carotid atheromas...
  42. ncbi Differential effects of peroxisome proliferator-activated receptor ligands and sulfonylurea plus statin treatment on plasma concentrations of adipokines in type 2 diabetes with dyslipidemia
    W H Yin
    Division of Cardiology, Department of Internal Medicine, Cheng Hsin General Hospital, and Institute of Clinical Medicine, Cardiovascular Research Center, National Yang Ming University, School of Medicine, Taipei, Taiwan
    Diabetes Metab 32:229-35. 2006
    ..We hypothesized that the combination of TZD+fibrate may be better than the sulfonylurea + statin approach regarding modifying the adipokine profile in diabetic patients with dyslipidemia...
  43. ncbi PPARs and other nuclear receptors in inflammation
    Giovanni Rizzo
    Department of Internal Medicine, University of Perugia, Via E dal Pozzo, 06122 Perugia, Italy
    Curr Opin Pharmacol 6:421-7. 2006
    ..In addition, peroxisome proliferator-activated receptors and liverXreceptors, in response to endogenous eicosanoids and oxysterols, respectively, modulate transcriptional pathways involved in inflammatory responses and lipid homeostasis...
  44. ncbi Activation of mouse and human peroxisome proliferator-activated receptors (alpha, beta/delta, gamma) by perfluorooctanoic acid and perfluorooctane sulfonate
    Margy L Takacs
    Reproductive Toxicology Division, National Health and Environmental Effects Research Laboratory, Office of Research and Development, US Environmental Protection Agency, Research Triangle Park, North Carolina 27711, USA
    Toxicol Sci 95:108-17. 2007
    ....
  45. ncbi [Peroxisome proliferator activated receptor ligands and angiogenesis]
    Mayumi Sato
    Medical R and D Center, Tokyo Metropolitan Institute for Medical Science
    Nippon Rinsho 63:603-8. 2005
    ..In this review, I highlight data concerning PPARs ligands involved in the biological mechanisms underlying antiangiogenesis...
  46. ncbi PPAR-gamma expression in pituitary tumours and the functional activity of the glitazones: evidence that any anti-proliferative effect of the glitazones is independent of the PPAR-gamma receptor
    Michelle N Emery
    Department of Endocrinology, St. Bartholomew's and the Royal London School of Medicine and Dentistry, London, UK
    Clin Endocrinol (Oxf) 65:389-95. 2006
    ..CONCLUSIONS :Our data suggest that the antiproliferative action of rosiglitazone is probably not via PPAR-gamma...
  47. ncbi Modulation of PPAR activity via phosphorylation
    Katherine A Burns
    Department of Veterinary and Biomedical Sciences and Center for Molecular Toxicology and Carcinogenesis, Penn State University, University Park, PA 16802, USA
    Biochim Biophys Acta 1771:952-60. 2007
    ..The review will summarize the known PPAR kinases that directly act on these receptors, the sites affected and the result of this modification on receptor activity...
  48. ncbi Peroxisome proliferator-activated receptors and liver X receptors in atherosclerosis and immunity
    Grant D Barish
    Gene Expression Laboratory, The Salk Institute for Biological Studies, La Jolla, CA 92037, USA
    J Nutr 136:690-4. 2006
    ....
  49. ncbi Tetrahydroisoquinoline PPARgamma agonists: design of novel, highly selective non-TZD antihyperglycemic agents
    James R Henry
    Lilly Research Laboratories, A Division of Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Bioorg Med Chem Lett 16:6293-7. 2006
    ..Novel tetrahydroisoquinolines have been developed as potent PPAR ligands. Evaluation of these compounds in PPARgamma responsive models of type 2 diabetes is described...
  50. ncbi The next generation of PPAR drugs: do we have the tools to find them?
    Barry G Shearer
    GlaxoSmithKline Research and Development, 5 Moore Drive, Research Triangle Park, NC 27709, USA
    Biochim Biophys Acta 1771:1082-93. 2007
    ..In this review we will discuss the side effects associated the PPARs, how the current drugs in clinical development were discovered and new concepts in how to screen for PPAR drugs...
  51. ncbi [PPAR family and its relationship to metabolic syndrome]
    Xiao-yan Zhang
    Peking University Diabetes Center, Department of Physiology and Pathophysiology, Peking University Health Science Center, Beijing 100083
    Sheng Li Ke Xue Jin Zhan 36:6-12. 2005
    ..Particular emphasis is placed on their pathogenic roles in the metabolic syndrome and the therapeutic utility of PPAR modulators in the treatment of type II diabetes...
  52. ncbi Nuclear receptors and autoimmune disease: the potential of PPAR agonists to treat multiple sclerosis
    Michael K Racke
    Department of Neurology, University of Texas Southwestern Medical Center, Dallas, 75390, USA
    J Nutr 136:700-3. 2006
    ..The fact that PPARalpha agonists have been used as therapeutic agents in humans to treat metabolic conditions for over 25 years with little toxicity makes them attractive candidates for use as adjunctive therapies in MS...
  53. ncbi Gaining weight: the Keystone Symposium on PPAR and LXR
    Michael Lehrke
    Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, and The Institute for Diabetes, Obesity, and Metabolism, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    Genes Dev 19:1737-42. 2005
    ..In recognition of this, a recent Keystone Symposium was devoted to these metabolic receptors. Here, we summarize some of the major highlights and future projections discussed at the meeting...
  54. ncbi Regulation of adiponectin receptor 1 in human hepatocytes by agonists of nuclear receptors
    Markus Neumeier
    Department of Internal Medicine I, University of Regensburg, D 93042 Regensburg, Germany
    Biochem Biophys Res Commun 334:924-9. 2005
    ..Elevated AdipoR1 induced by hepatotoxic troglitazone may indicate a role of this receptor in adiponectin-mediated beneficial effects in liver damage...
  55. ncbi Peroxisome proliferator-activated receptors (PPARs) in skin health, repair and disease
    Liliane Michalik
    Center for Integrative Genomics, National Research Center Frontiers in Genetics, University of Lausanne, Genopode Building, CH 1015 Lausanne, Switzerland
    Biochim Biophys Acta 1771:991-8. 2007
    ..Due to their collective diverse functions in skin biology, PPARs represent a major research target for the understanding and treatment of many skin diseases, such as benign epidermal tumors, papillomas, acne vulgaris and psoriasis...
  56. ncbi Caloric restriction results in decreased expression of peroxisome proliferator-activated receptor superfamily in muscle of normal and long-lived growth hormone receptor/binding protein knockout mice
    Michal M Masternak
    Department of Internal Medicine, Geriatrics Research, Southern Illnois University School of Medicine, Springfield, 62794 9628, USA
    J Gerontol A Biol Sci Med Sci 60:1238-45. 2005
    ..This suggested metabolic change clearly does not affect whole-body insulin action. These findings suggest that whole-animal insulin sensitivity is not regulated through skeletal muscle insulin action...
  57. ncbi Peroxisome proliferator-activated receptor alpha, delta, gamma1 and gamma2 expressions are present in human monocyte-derived dendritic cells and modulate dendritic cell maturation by addition of subtype-specific ligands
    M A Jakobsen
    Department of Clinical Immunology, Odense University Hospital, Odense, Denmark
    Scand J Immunol 63:330-7. 2006
    ..Our data suggest that naturally occurring PPAR ligands like fatty acids and fatty acid derivates have anti-inflammatory effects by redirecting DC into a less stimulatory mode...
  58. ncbi LXR and PPAR activators stimulate cholesterol sulfotransferase type 2 isoform 1b in human keratinocytes
    Yan J Jiang
    Department of Medicine, University of California San Francisco, San Francisco, CA 94121, USA
    J Lipid Res 46:2657-66. 2005
    ..Thus, LXR and PPAR activators regulate the expression of SULT2B1b, the key enzyme in the synthesis of CS, which is a potent regulator of epidermal differentiation and corneocyte desquamation...
  59. ncbi The peroxisome proliferator-activated receptor N-terminal domain controls isotype-selective gene expression and adipogenesis
    Sarah Hummasti
    Howard Hughes Medical Institute, Department of Pathology and Laboratory Medicine, University of California, Los Angeles, California 90095-1662, USA
    Mol Endocrinol 20:1261-75. 2006
    ..A more detailed understanding of the mechanisms by which the individual PPARs differentially regulate gene expression should aid in the design of more effective drugs, including tissue- and target gene-selective PPAR modulators...
  60. ncbi Mitochondria, ciglitazone and liver: a neglected interaction in biochemical pharmacology
    Roberto Scatena
    Istituto di Biochimica e Biochimica Clinica, Universita Cattolica, Rome, Italy
    Eur J Pharmacol 567:50-8. 2007
    b>Peroxisome proliferator activated receptors (PPARs) are a class of nuclear receptors now actively investigated for their involvement in lipid and glucidic metabolism, immune regulation and cell differentiation...
  61. ncbi Oxidative stress influences cholesterol efflux in THP-1 macrophages: role of ATP-binding cassette A1 and nuclear factors
    Valérie Marcil
    Centre de Recherche, CHU Sainte Justine, Universite de Montreal, 3175, Cote Ste Catherine, Montreal Quebec, Canada H3T 1C5
    Cardiovasc Res 72:473-82. 2006
    ..Our aim was to characterize the effects of oxidative stress on key receptors of macrophage cholesterol homeostasis, on the nuclear transcription factors PPAR and LXR regulating their expression, and on macrophage cholesterol handling...
  62. ncbi Rational drug design and PPAR agonists
    Riccardo Perfetti
    Department of Medical Sciences, Amgen Inc, One Amgen Center Drive, Mail Stop 38 3 A, Thousand Oaks, CA 91320 1799, USA
    Curr Diab Rep 5:340-5. 2005
    ....
  63. ncbi Peroxisome-proliferator-activated receptors and the control of levels of prostaglandin-endoperoxide synthase 2 by arachidonic acid in the bovine uterus
    E Linda R Sheldrick
    Division of Animal Physiology, School of Biosciences, University of Nottingham, Sutton Bonington Campus, Loughborough LE12 5RD, UK
    Biochem J 406:175-83. 2007
    ..The results are consistent with the hypothesis that arachidonic acid acts via PPARalpha to increase PTGS2 levels in bovine endometrial stromal cells...
  64. ncbi Gender and genetic differences in bladder smooth muscle PPAR mRNA in a porcine model of the metabolic syndrome
    Heather M Mattern
    Department of Medical Pharmacology and Physiology, University of Missouri, MA415 Medical Sciences Building, Columbia, MO 65212, USA
    Mol Cell Biochem 302:43-9. 2007
    ..We conclude that PPAR profiles in BSM may contribute to the susceptibility of BSM to lipotoxicity in the metabolic syndrome...
  65. ncbi Changes in expression levels of genes involved in fatty acid metabolism: upregulation of all three members of the PPAR family (alpha, gamma, delta) and the newly described adiponectin receptor 2, but not adiponectin receptor 1 during neonatal cardiac deve
    Michael Steinmetz
    Department of Pediatric Cardiology and Intensive Care Medicine, Georg August University Gottingen, Robert Koch Str 40, 37075 Gottingen, Germany
    Basic Res Cardiol 100:263-9. 2005
    ..The aim of this study was to investigate the changes in mRNA expression levels of genes involved in the control of cardiac fatty acid metabolism in the transition from neonatal to adult life...
  66. ncbi Induction of adiponectin by natural and synthetic phenolamides in mouse and human preadipocytes and its enhancement by docosahexaenoic acid
    Yoshimitsu Yamazaki
    Institute for Biological Resources and Functions, National Institute of Advanced Industrial Science and Technology, 1 1 1 Higashi, Tsukuba, Ibaraki 305 8566, Japan
    Life Sci 82:290-300. 2008
    ....
  67. ncbi Nuclear hormone receptors and intestinal inflammation
    Gary D Wu
    Gastroenterology 133:1068. 2007
  68. ncbi Dissociation of oxidant production by peroxisome proliferator-activated receptor ligands from cell death in human cell lines
    Elisa B Atarod
    Division of Pharmacology and Toxicology, College of Pharmacy, University of Texas at Austin, Austin, TX 78712-0125, USA
    Free Radic Biol Med 37:36-47. 2004
    ..These data also suggest that oxidant production induced by PPARalpha ligands originates in the mitochondria...
  69. ncbi PPARalpha agonists stimulate progastrin production in human colorectal carcinoma cells
    Shamilah Lachal
    Department of Surgery ARMC, University of Melbourne, Department of Surgery, Austin Health, Heidelberg, Victoria 3084, Australia
    Regul Pept 120:243-51. 2004
    ..These studies have revealed a relationship between PPARs and gastrin, two regulatory molecules implicated in the pathogenesis of CRC...
  70. ncbi Novel oxazole containing phenylpropane derivatives as peroxisome proliferator activated receptor agonists with hypolipidemic activity
    H Pingali
    Zydus Research Centre, Sarkhej Bavla N H 8A Moraiya, Ahmedabad, India
    Pharmazie 63:497-502. 2008
    ..Compounds 3c and 3d showed the desired predominant PPARalpha activity and excellent tryiglyceride reduction in vivo and were selected as lead compounds for further development as hypolipidemic agents...
  71. ncbi Tissue-specific expression of PPAR mRNAs in diabetic rats and divergent effects of cilostazol
    Furong Wang
    Provincial Hospital affiliated to Shandong University, Jinan, Shandong 250021, China
    Can J Physiol Pharmacol 86:465-71. 2008
    ..In conclusion, mRNA expression of PPARs is tissue-specific in diabetes and may be differently affected by cilostazol, possibly because of its tissue-specific effects on cAMP content...
  72. ncbi PPAR agonists: multimodal drugs for the treatment of type-2 diabetes
    Barbara Gross
    Institut Pasteur de Lille, 1 rue du Prof Calmette, Lille, F 59019, France
    Best Pract Res Clin Endocrinol Metab 21:687-710. 2007
    ..This chapter focuses on the PPAR agonists currently used in the clinic, as well as on the discovery and development of the next generation of PPAR agonists...
  73. ncbi 1. Peroxisome proliferator-activated receptor gamma (PPARgamma) ligands and their therapeutic utility
    Brad R Henke
    Metabolic and Viral Diseases Drug Discovery Research, GlaxoSmithKline, 5 Moore Drive, Research Triangle Park, NC 27709, USA
    Prog Med Chem 42:1-53. 2004
  74. ncbi [Nuclear receptor PPAR and hepatology: pathophysiological and therapeutical aspects]
    S Dharancy
    INSERM U795, Boulevard du Professeur Jules Leclercq, 59037 Lille, France
    Gastroenterol Clin Biol 32:339-50. 2008
    ..In terms of therapy, animal studies and human trials have been conducted in steatopathies. However, clinicians have to be aware of potential specific side effects related to glitazones especially on cardiovascular system...
  75. ncbi Peroxisome proliferator-activated receptors mediate host cell proinflammatory responses to Pseudomonas aeruginosa autoinducer
    Aruna Jahoor
    Department of Cell Biology and Biochemistry, Texas Tech University Health Sciences Center, 3601 4th St, Lubbock, TX 79430, USA
    J Bacteriol 190:4408-15. 2008
    ..These data identify PPARbeta/delta and PPARgamma as putative mammalian 3OC(12)-HSL receptors and suggest that PPARgamma agonists may be employed as anti-inflammatory therapeutics for P. aeruginosa infections...
  76. ncbi In vivo imaging reveals selective peroxisome proliferator activated receptor modulator activity of the synthetic ligand 3-(1-(4-chlorobenzyl)-3-t-butylthio-5-isopropylindol-2-yl)-2,2-dimethylpropanoic acid (MK-886)
    Andrea Biserni
    Center of Excellence on Neurodegenerative Diseases, Department of Pharmacological Sciences, University of Milan, Via Balzaretti 9, 20133 Milan, Italy
    Mol Pharmacol 73:1434-43. 2008
    ..The results of this study, demonstrating the usefulness of reporter mice, may open new avenues for the development of innovative drugs for cardiovascular, endocrine, neural, and skeletal systems characterized by limited side effects...
  77. ncbi Effect of medium- and long-chain fatty acid diets on PPAR and SREBP-1 expression and glucose homeostasis in ACBP-overexpressing transgenic rats
    S Oikari
    Department of Biotechnology and Molecular Medicine, A I Virtanen Institute for Molecular Sciences, Kuopio, Finland
    Acta Physiol (Oxf) 194:57-65. 2008
    ..As the physiological relevance of ACBP in the regulation of lipid metabolism under high fat diets is unclear, we investigated the influence of such diets on the metabolic responses in ACBP-overexpressing rats...
  78. ncbi Transcriptome analysis of endometrial cancer identifies peroxisome proliferator-activated receptors as potential therapeutic targets
    Cathrine M Holland
    Department of Pathology, University of Cambridge, The Rosie Hospital, Box 223, Level 2, Robinson Way, Cambridge CB2 2SW, United Kingdom
    Mol Cancer Ther 3:993-1001. 2004
    ..These results support further investigation of members of the PPAR/retinoid X receptor pathway as novel therapeutic targets in endometrial cancer...
  79. ncbi Lipid synthesis in macrophages during inflammation in vivo: effect of agonists of peroxisome proliferator activated receptors alpha and gamma and of retinoid X receptors
    E N Posokhova
    Institute of Internal Medicine, Siberian Branch of the Russian Academy of Medical Sciences, Novosibirsk, Russia
    Biochemistry (Mosc) 73:296-304. 2008
    The effects of peroxisome proliferator activated receptors alpha and gamma (PPAR-alpha and PPAR-gamma) and retinoid X receptor (RXR) agonists upon synthesis and accumulation of lipids in murine C57Bl macrophages during inflammation ..
  80. ncbi Preventing the progression of diabetes mellitus
    Brian V Reamy
    Am Fam Physician 71:425. 2005
  81. ncbi PPAR and LXR activators regulate ABCA12 expression in human keratinocytes
    Yan J Jiang
    Metabolism Section, Department of Veterans Affairs Medical Center, Northern California Institute for Research and Education, University of California at San Francisco, San Francisco, California 94121, USA
    J Invest Dermatol 128:104-9. 2008
    ..Together, our data demonstrate that PPAR and LXR activators increase ABCA12 expression, providing an additional mechanism by which PPAR and LXR activators promote epidermal permeability barrier homeostasis...
  82. ncbi A PPARs cross-talk concertedly commits C6 glioma cells to oligodendrocytes and induces enzymes involved in myelin synthesis
    Andrea V Leisewitz
    Facultad de Ciencias Biologicas, Department of Cellular and Molecular Biology, Centro de Regulación Celular y Patología CRCP, Millennium Institute for Fundamental and Applied Biology, P Universidad Catolica de Chile, Alameda, Santiago, Chile
    J Cell Physiol 217:367-76. 2008
    b>Peroxisome proliferator activated receptors (PPARs, alpha, beta/delta, gamma) control lipid homeostasis and differentiation in various tissues and tumor cells...
  83. ncbi PPARs and their metabolic modulation: new mechanisms for transcriptional regulation?
    W Ahmed
    Cardiovascular Division, Harvard Medical School, Brigham and Women s Hospital, Boston, MA, USA
    J Intern Med 262:184-98. 2007
    ....
  84. ncbi Synthesis and biological activity of benzoxazole containing thiazolidinedione derivatives
    Raok Jeon
    College of Pharmacy, Sookmyung Women s University, Chungpa dong 2 Ka, Yongsan Ku, Seoul 140 742, Korea
    Arch Pharm Res 27:1099-105. 2004
    ..Most compounds tested were identified as potent PPARgamma agonists...
  85. ncbi PPARs special issue: anchoring the present to explore the future
    Beatrice Desvergne
    University of Lausanne, Genopode, 1015 Lausanne, Switzerland
    Biochim Biophys Acta 1771:913-4. 2007
  86. ncbi Phosphorylation of PPARs: from molecular characterization to physiological relevance
    Claire Diradourian
    , Institut Cochin, INSERM U567 CNRS UMR8104, , 24, rue du Faubourg Saint Jacques 75014 Paris, France
    Biochimie 87:33-8. 2005
    ..Molecular consequences are multiple, including changes in ligand affinity, DNA binding, recruitment of transcriptional cofactors, proteasome degradation... Finally, the physiological relevance of PPAR phosphorylation is discussed...
  87. ncbi Modulation of PPAR in aging, inflammation, and calorie restriction
    Bokyung Sung
    College of Pharmacy, Aging Tissue Bank, Pusan National University, Busan, Korea
    J Gerontol A Biol Sci Med Sci 59:997-1006. 2004
    ..Based on these findings, we conclude that the altered expression of PPARs may be due to increased oxidative stress with age, and that CR prevents these decreases through its antioxidative action...
  88. ncbi An overview of the effect of linoleic and conjugated-linoleic acids on the growth of several human tumor cell lines
    Marina Maggiora
    Dipartimento di Medicina e Oncologia Sperimentale, , Torino, Italy
    Int J Cancer 112:909-19. 2004
    ..In conclusion, CLA may be regarded as a component of the diet that exerts antineoplastic activity and its effect may be antiproliferative or pro-apoptotic...
  89. ncbi Rosiglitazone induces interleukin-1 receptor antagonist in interleukin-1beta-stimulated rat synovial fibroblasts via a peroxisome proliferator-activated receptor beta/delta-dependent mechanism
    David Moulin
    UMR 7561 CNRS Université Henri Poincaré Nancy 1, Vandoeuvre les Nancy, France
    Arthritis Rheum 52:759-69. 2005
    ....
  90. ncbi Effects of cold stress on the messenger ribonucleic acid levels of peroxisome proliferator-activated receptor-{gamma} in spleen, thymus, and bursa of Fabricius of chickens
    J T Wang
    College of Veterinary Medicine, Northeast Agricultural University, Harbin 150030, P R China
    Poult Sci 88:2549-54. 2009
    ..The magnitude and direction of change in PPAR-gamma gene expression differs with the type of cold stress applied and also varies by tissue...
  91. ncbi [Effect of peroxisome proliferators activated receptor gamma and its ligand on airway mucus hypersecretion in rats]
    Wei Jia Liu
    Department of Respiratory Medicine, Sichuan University West China Hospital, Chengdu 610041, China
    Zhonghua Jie He He Hu Xi Za Zhi 32:282-6. 2009
    ..To explore the effect and the molecular mechanisms of peroxisome proliferators activated receptor gamma (PPAR-gamma) and its ligand on airway mucus hypersecretion...
  92. ncbi Peroxisomal beta-oxidation and steatohepatitis
    M S Rao
    Department of Pathology, Northwestern University Medical School, Chicago, Illinois, USA
    Semin Liver Dis 21:43-55. 2001
    ....
  93. ncbi Peroxisome proliferator-activated receptors, coactivators, and downstream targets
    C Qi
    Department of Pathology, Northwestern University Medical School, Chicago, Illinois 60611, USA
    Cell Biochem Biophys 32:187-204. 2000
    ....
  94. ncbi Relationship between different stages of the corpus luteum and the expression of the peroxisome proliferator-activated receptor gamma protein in bovine large lutein cells
    T Viergutz
    Research Institute for the Biology of Farm Animals, Dummerstorf, Germany
    J Reprod Fertil 118:153-61. 2000
    ....
  95. ncbi Modulation of peroxisome proliferator-activated receptors (PPARs) by PPAR(alpha)- and PPAR(gamma)-specific ligands and by 17beta-estradiol in isolated zebrafish hepatocytes
    A Ibabe
    Biologia Zelularra eta Histologia Laborategia, Zoologia eta Animali Biologia Zelularra Saila, Zientzia eta Teknologia Fakultatea, Euskal Herriko Unibertsitatea Universidad del País Vasco, 644 PK, Bilbao E 48080, Basque Country, Spain
    Toxicol In Vitro 19:725-35. 2005
    ..Further studies are needed to identify how the expression of different PPAR subtypes is regulated and to elucidate the implication of PPAR subtypes in zebrafish cell functions...
  96. ncbi Regulation of the peroxisomal beta-oxidation-dependent pathway by peroxisome proliferator-activated receptor alpha and kinases
    N Latruffe
    LBMC, University of Burgundy, 21000 Dijon, France
    Biochem Pharmacol 60:1027-32. 2000
    ..Eur J Biochem 230:316-321, 1995). From all these findings, PPAR alpha and kinases appear to play an important role in lipid homeostasis...
  97. ncbi Potent and selective PPAR-alpha agonist LY518674 upregulates both ApoA-I production and catabolism in human subjects with the metabolic syndrome
    John S Millar
    Departments of Pharmacology, University of Pennsylvania, 652 BRB II III, 421 Curie Blvd, Philadelphia, PA 19104, USA
    Arterioscler Thromb Vasc Biol 29:140-6. 2009
    ..We sought to determine the effect of a potent and highly specific PPAR-alpha agonist, LY518674, on apoA-I, apoA-II, and apoB-100 kinetics in humans with metabolic syndrome and low levels of HDL cholesterol (C)...
  98. ncbi Physiological difference between obese (fa/fa) Zucker rats and lean Zucker rats concerning adiponectin
    Fumiki Oana
    Division of Discovery Research, Kissei Pharmaceutical Co Ltd, 4365 1, Hotaka, Nagano 399 8304, Japan
    Metabolism 54:995-1001. 2005
    ....
  99. ncbi Differential gene regulation in human versus rodent hepatocytes by peroxisome proliferator-activated receptor (PPAR) alpha. PPAR alpha fails to induce peroxisome proliferation-associated genes in human cells independently of the level of receptor expresso
    J W Lawrence
    Department of Safety Assessment, Merck Research Laboratories, Merck and Co, Inc, West Point, Pennsylvania 19486, USA
    J Biol Chem 276:31521-7. 2001
    ..These results suggest that other factors besides PPAR alpha levels determine the species-specific response of human and rat hepatocytes to the induction of PP...
  100. ncbi Regulation of PPAR gamma gene expression by nutrition and obesity in rodents
    A Vidal-Puig
    Department of Medicine, Beth Israel Hospital, Boston, Massachusetts 02215, USA
    J Clin Invest 97:2553-61. 1996
    ..These findings demonstrate in vivo modulation of PPAR gamma mRNA levels over a fourfold range and provide an additional level of regulation for the control of adipocyte development and function...
  101. ncbi Peroxisome proliferator-activated receptors gamma and alpha mediate in vivo regulation of uncoupling protein (UCP-1, UCP-2, UCP-3) gene expression
    L J Kelly
    Department of Molecular Endocrinology, Merck Research Laboratories, Rahway, New Jersey 07065, USA
    Endocrinology 139:4920-7. 1998
    ..PPAR alpha activation in mice is sufficient to induce liver UCP-2 expression...

Research Grants89

  1. Limiting Inflammation in the CF Lung
    Pamela Davis; Fiscal Year: 2007
    ..The name of the principal investigator/program director must be provided at the top of each printed page and each continuation page. RESEARCH GRANT TABLE OF CONTENTS PageNumbers Face Page ' Description, ..
  2. Beta-cell Compensation in Partial Pancreatectomy Mice
    JOHN L LEAHY; Fiscal Year: 2010
    ....
  3. Molecular targeting of PPAR-delta in colon cancer
    Imad Shureiqi; Fiscal Year: 2010
    ..This improved understanding is expected to help determine whether PPAR-d would be a suitable molecular target for development of new drugs to treat colon cancer. ..
  4. 15-LOX-1 effects on colitis and colon cancer
    Imad Shureiqi; Fiscal Year: 2009
    ..This improved understanding is expected to facilitate the identification of molecular targets for new strategies for colon cancer prevention. ..
  5. 15-LOX-1 effects on colitis and colon cancer
    Imad Shureiqi; Fiscal Year: 2010
    ..This improved understanding is expected to facilitate the identification of molecular targets for new strategies for colon cancer prevention. ..
  6. MOLECULAR BASIS OF HIV LIPODYSTROPHY: ROLE OF VPR
    Ashok Balasubramanyam; Fiscal Year: 2003
    ....
  7. ROLE OF PPAR GAMMA IN LUPUS NEPHRITIS
    Gary Gilkeson; Fiscal Year: 2005
    ..As agonists of PPAR gamma (the thiazolidinediones) are already approved for human use, insight gained from these studies can be quickly translated into human trials. ..
  8. PPAR-gamma Signaling in Normal Pilosebaceous Units and in Scarring Alopecia
    Pratima Karnik; Fiscal Year: 2010
    ..PHS 398/2590 (Rev. 11/07) Page Continuation Format Page ..
  9. Transcriptional Control of Macrophage in Atherogenesis
    Ajay Chawla; Fiscal Year: 2010
    ..activated macrophages in tissues is absolutely dependent on the transcriptional activity of Peroxisome Proliferator Activated Receptors gamma and delta (PPAR gamma and delta), providing a mechanistic basis for the protective ..
  10. Action of Anabolic Factors on Bone Formation in Mice
    MARJA MARIE HURLEY; Fiscal Year: 2010
    ....
  11. Action of Anabolic Factors on Bone Formation in Mice
    Marja Hurley; Fiscal Year: 2009
    ....
  12. Role of PPARbeta in colon carcinogenesis
    Jeffrey Peters; Fiscal Year: 2007
    ..abstract_text> ..
  13. Cardiac metabolism and heart failure
    Rong Tian; Fiscal Year: 2009
    ..Results from the study will provide a basis for optimizing cardiac metabolism as part of the treatment strategy for heart failure. This is particularly important for patients with metabolic disorders such as obesity or diabetes. ..
  14. Pathophysiology of PPARgamma in the lung
    Hong Du; Fiscal Year: 2009
    ..These studies will provide new approaches to design strategies and discover drugs to combat emphysema and COPD. ..
  15. Pathophysiology of PPARgamma in the lung
    Hong Du; Fiscal Year: 2010
    ..These studies will provide new approaches to design strategies and discover drugs to combat emphysema and COPD. ..
  16. Pathophysiology of PPARgamma in the lung
    Hong Du; Fiscal Year: 2010
    ..These studies will provide new approaches to design strategies and discover drugs to combat emphysema and COPD. ..
  17. The function(s) and regulation of PPARs in the ovary
    Carolyn Komar; Fiscal Year: 2003
    ....
  18. Pparg In Macrophage Promote Hematoma Absorption After Intracerebral Hemorrhage
    Xiurong Zhao; Fiscal Year: 2007
    ..Our long-term goal is to identify the molecular mechanism of PPAR? in phagocytosis/hematoma resolution and neuroprotection after ICH for future evaluation as a potential therapeutic target. ..
  19. Transcriptional Repression of PPARgamma-2 by Glucocorticoid-Induced Leucine Zippe
    Xing Ming Shi; Fiscal Year: 2010
    ..Thus, understanding how PPAR(2 can be negatively regulated, a focus of this study, may lead to new therapies for treating osteoporosis and obesity. ..
  20. Transcriptional Repression of PPARgamma-2 by Glucocorticoid-Induced Leucine Zippe
    Xingming Shi; Fiscal Year: 2009
    ..Thus, understanding how PPAR(2 can be negatively regulated, a focus of this study, may lead to new therapies for treating osteoporosis and obesity. ..
  21. Transcriptional Repression of PPARgamma-2 by Glucocorticoid-Induced Leucine Zippe
    Xing Ming Shi; Fiscal Year: 2010
    ..Thus, understanding how PPAR(2 can be negatively regulated, a focus of this study, may lead to new therapies for treating osteoporosis and obesity. ..
  22. PEROXISOME PROLIFERATORS AND THE CELL CYCLE
    JANE ISHMAEL; Fiscal Year: 2002
    ..In general it is hoped that these studies will increase our understanding of the relationship between cell proliferation and hepatocarcinogenesis induced by nongenotoxic carcinogens. ..
  23. Role of PPAR-gamma Isoforms in Regulation of Macrophage apoE & LPL Expression
    Jheem Medh; Fiscal Year: 2006
    ..Information about ligand specificities of individual PPAR-g protein isoforms and their specific gene targets will allow for the selective induction of desirable genes and repression of harmful ones. ..
  24. Association of PPAR gamma ligands & colonic neoplasia
    James Lewis; Fiscal Year: 2006
    ..Our results will allow us to translate the existing in vitro and in vivo observations to the intact human colon and could lead to further chemoprevention strategies. ..
  25. GLUCOSE UTILIZATION IN HYPERTROPHIED AND FAILING HEARTS
    Rong Tian; Fiscal Year: 2007
    ..3) increasing glucose transport in failing hearts improves energy supply and contractile performance. 4) increasing glucose transport enhances the efficacy of SERCA2a overexpression in the treatment of heart failure. ..
  26. The PPAR-delta pathway in neural function and Hungtington's disease neuropatholog
    Albert R La Spada; Fiscal Year: 2010
    ....
  27. Cellular Selenium Status and PGJ2 Metabolism
    KUMBLE SANDEEP PRABHU; Fiscal Year: 2009
    ....
  28. H.Pylori Relationship to Digestive Diseases and Cancer
    Richard Peek; Fiscal Year: 2007
    ..pylori-induced carcinogenesis and facilitate identification of potential therapeutic targets, but may also provide insights into other malignancies that arise within the context of inflammatory states. ..
  29. 5-LOX-1 and Clinical Chemoprevention of Colon Tumors
    Imad Shureiqi; Fiscal Year: 2007
    ..If our hypothesis is confirmed, efforts can be directed to develop chemopreventive interventions that specifically target the GATA-6 and 15-LOX-1 signaling pathway. ..
  30. Chemoprevention of Pituitary Corticotroph Tumors
    Anthony Heaney; Fiscal Year: 2006
    ..Our ultimate goal is to develop a rationale for clinical application of these PPAR-gamma ligands as a novel medical therapy in Cushing's disease. ..
  31. Gene expression and anemia of chronic renal failure
    Saul Nurko; Fiscal Year: 2007
    ..abstract_text> ..
  32. Structural and functional studies of the nuclear receptor PPARgamma
    H Eric Xu; Fiscal Year: 2007
    ....
  33. Elucidation of injury pathways in alcoholic liver disease and development of prev
    Albert J Fornace; Fiscal Year: 2010
    ..Results will improve approaches to prevent or treat alcoholic liver disease with a solid mechanistic rationale. ..
  34. Structural and functional studies of the nuclear receptor PPARgamma
    H Eric Xu; Fiscal Year: 2009
    ....
  35. Structural and functional studies of the nuclear receptor PPARgamma
    H Eric Xu; Fiscal Year: 2010
    ....
  36. The impact of PPAR-gamma and estrogen receptor crosstalk on insulin action
    Andrea Hevener; Fiscal Year: 2007
    ..Additionally our goal is to elucidate the importance of nuclear receptor crosstalk in the regulation of gene transcription and show that aberrant crosstalk is an underlying mechanism of insulin resistance and obesity. ..
  37. Programmed Adipogenesis and Lipid Dysregulation
    Mina Desai; Fiscal Year: 2010
    ..As increased body fat is one of the key features of obesity, the proposed studies will investigate the mechanism in which fat signaling factors are altered. ..